Search

Your search keyword '"pomalidomide"' showing total 54 results
Start Over Descriptor "pomalidomide" Publication Type Magazines
54 results on '"pomalidomide"'

1. EMA human medicine committee recommends approval of Sanofi's Sarclisa to treat transplant-ineligible newly diagnosed multiple myeloma

Subjects
Sanofi S.A., Sarclisa (Medication), Care and treatment, Carfilzomib, Pomalidomide, Multiple myeloma -- Care and treatment, Stem cells, Pharmaceutical industry, Stem cell transplantation, Stem cells -- Transplantation
Abstract

The European Medicines Agency (EMA)'s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone [...]

Published
2024

2. Johnson & Johnson seeks US & EU approvals for Darzalex Faspro/Darzalex as subcutaneous monotherapy for high-risk smoldering multiple myeloma

Subjects
Johnson & Johnson, United States. Food and Drug Administration, European Union, Darzalex Faspro (Medication), Darzalex (Medication), Drug therapy, Carfilzomib, Pomalidomide, Multiple myeloma -- Drug therapy, Daratumumab, Pharmaceutical industry, Drug approval
Abstract

Johnson & Johnson announced the submission of regulatory applications to the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) seeking approval of a new indication for Darzalex [...]

Published
2024

3. My Bioidentical Hormone Creams Are Killing Me!

Author

Dach, Jeffrey

Subjects
United States. Food and Drug Administration, Prescription writing, Pomalidomide, Menopause, Drug approval, Health
Abstract

With the publication of the July 2020 NASEM report, I was astonished to learn that for the past 20 years, compounded bioidentical hormones have been killing everyone. (1) If only [...]

Published
2020

4. Ascentage Pharma gets China NMPA approvals for two phase Ib/II studies of Bcl-2 inhibitor APG-2575 to treat Waldenstrom macroglobulinemia and multiple myeloma

Subjects
Clinical trials, Ibrutinib -- Product development, Pomalidomide, Medical research, Multiple myeloma -- Drug therapy, Drug approval, Pharmaceuticals and cosmetics industries
Abstract

Ascentage Pharma, a clinical-stage biotechnology company, announced that the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has approved two phase Ib/II clinical studies of its [...]

Published
2020

5. Janssen seeks US & European approvals for Darzalex Faspro/Darzalex SC in combo with pomalidomide & dexamethasone to treat r/r multiple myeloma

Subjects
United States. Food and Drug Administration, Johnson & Johnson, Pomalidomide, Hyaluronidase, Multiple myeloma -- Drug therapy, Daratumumab, Pharmaceutical industry, Dexamethasone, Pharmaceuticals and cosmetics industries, European Union, Darzalex (Medication)
Abstract

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of regulatory applications to the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) seeking approval of [...]

Published
2020

6. Natco Pharma's partner, Breckenridge Pharma gets US FDA approval for pomalidomide capsules

Subjects
United States. Food and Drug Administration, Bristol-Myers Squibb Co., Natco Pharma Ltd., Celgene Corp., Pomalidomide, Multiple myeloma -- Drug therapy, Drug approval, Pharmaceuticals and cosmetics industries
Abstract

Natco Pharma Limited announced that its marketing partner, Breckenridge Pharmaceutical Inc., has received final approval for its Abbreviated New Drug Application (ANDA) for pomalidomide capsules, from the US Food and [...]

Published
2020

7. Lenalidomide in Relapsed and Refractory Multiple Myeloma

Subjects
Physical fitness, Angiogenesis inhibitors, Pomalidomide, Recurrence (Disease), Multiple myeloma, Lenalidomide, Health
Abstract

2020 OCT 24 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- According to news reporting based on a preprint abstract, our journalists obtained [...]

Published
2020

8. Complejo Asistencial Universitario de Salamanca Researchers Provide New Insights into Multiple Myeloma (Protein Translation Inhibition is Involved in the Activity of the Pan-PIM Kinase Inhibitor PIM447 in Combination with ...)

Subjects
Physical fitness, Pomalidomide, Cancer research, Biochemistry, Health
Abstract

2020 OCT 17 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Data detailed on multiple myeloma have been presented. According to news reporting [...]

Published
2020

10. Researchers at Second Military Medical University Release New Data on Colon Cancer (Discovery of Novel PDEd Degraders for the Treatment of KRAS Mutant Colorectal Cancer)

Subjects
Protein-protein interactions, Physical fitness, Pomalidomide, Cancer research, Colorectal cancer -- Care and treatment, Health
Abstract

2020 AUG 1 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators discuss new findings in Oncology - Colon Cancer. According to news [...]

Published
2020

11. Research Data from University of Texas MD Anderson Cancer Center Update Understanding of Myeloma (The Novel Protein Homeostatic Modulator Btx306 Is Active In Myeloma and Overcomes Bortezomib and Lenalidomide Resistance)

Subjects
Physical fitness, Angiogenesis inhibitors, Thiophene, Cancer, Pomalidomide, Cancer research, Proteins, Lenalidomide, Health, University of Texas. M.D. Anderson Cancer Center
Abstract

2020 AUG 1 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Data detailed on Oncology - Myeloma have been presented. According to news [...]

Published
2020

12. Oncopeptides seeks US FDA accelerated approval for melflufen in combo with dexamethasone to treat multiple myeloma

Subjects
United States. Food and Drug Administration, Pomalidomide, Multiple myeloma -- Drug therapy, Daratumumab, Drug approval, Dexamethasone, Pharmaceuticals and cosmetics industries
Abstract

Oncopeptides, a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases, announced that the company submits a New Drug Application (NDA) to the US Food and [...]

Published
2020

13. Oncopeptides presents positive results from phase 2 HORIZON study of melflufen in combo with dexamethasone to treat RRMM at EHA meeting

Subjects
United States. Food and Drug Administration, Pomalidomide, Multiple myeloma, Daratumumab, Dexamethasone -- Product development, Pharmaceuticals and cosmetics industries
Abstract

Oncopeptides AB announces that the full top-line results from the pivotal phase 2 HORIZON study, evaluating intravenous melflufen in combination with dexamethasone in patients with relapsed refractory multiple myeloma (RRMM), [...]

Published
2020

14. Sanofi's Sarclisa in combo with pom-dex receives European approval to treat adults with relapsed and refractory MM

Subjects
Sanofi S.A., Monoclonal antibodies, Pomalidomide, Multiple myeloma -- Care and treatment -- Development and progression, Drug approval, Adults, Antibodies, Dexamethasone, Lenalidomide, Glucocorticoids, Antigenic determinants, Diseases, Pharmaceuticals and cosmetics industries, European Union. European Commission
Abstract

Sanofi has announced that the European Commission (EC) has approved Sarclisa (isatuximab) in combination with pomalidomide and dexamethasone (pom-dex) for the treatment of adult patients with relapsed and refractory multiple [...]

Published
2020

15. Sanofi reports EC approves Sarclisa for relapsed and refractory multiple myeloma

Subjects
Sanofi S.A., Pomalidomide, Recurrence (Disease) -- Care and treatment -- Development and progression, Multiple myeloma -- Care and treatment -- Development and progression, Drug approval, Dexamethasone, Lenalidomide, Glucocorticoids, Diseases, Business, News, opinion and commentary
Abstract

The European Commission has approved Sarclisa in combination with pomalidomide and dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two [...]

Published
2020

16. Oncopeptides announces positive results from OCEAN study between melflufen & pomalidomide in patients with RRMM

Subjects
Pomalidomide, Multiple myeloma -- Care and treatment -- Development and progression, Comparative literature, Recurrence (Disease), Oceans, Diseases, Pharmaceuticals and cosmetics industries
Abstract

Oncopeptides AB announces that patients in the OCEAN study stay on treatment longer than previously estimated. As a consequence, top-line results are estimated for H1 2021 instead of previously communicated [...]

Published
2020

17. New Multiple Myeloma Study Results Reported from University Hospital Heidelberg (Mor202, a Novel Anti-cd38 Monoclonal Antibody, In Patients With Relapsed or Refractory Multiple Myeloma: a First-in-human, Multicentre, Phase 1-2a Trial)

Subjects
MorphoSys AG, Physical fitness, Monoclonal antibodies, Pomalidomide, Recurrence (Disease) -- Care and treatment, Biotechnology industries, Multiple myeloma -- Care and treatment, Biological products industry, Antibodies, Finance, Editors, Health
Abstract

2020 MAY 30 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- New research on Oncology - Multiple Myeloma is the subject of a [...]

Published
2020

18. Oncopeptides completes enrollment in phase 3 study OCEAN to treat relapsed refractory MM

Subjects
Pomalidomide, Medical research, Multiple myeloma -- Care and treatment, Comparative literature, Recurrence (Disease), Pharmaceutical industry, Oceans, Diseases, Pharmaceuticals and cosmetics industries
Abstract

Oncopeptides AB, a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases, announced the successful completion of enrollment in the pivotal phase 3 study OCEAN for [...]

Published
2020

19. US FDA approves Bristol Myers Squibb's Pomalyst for AIDS-related & HIV-negative Kaposi sarcoma

Subjects
United States. Food and Drug Administration, HIV patients, Kaposi's sarcoma, Highly active antiretroviral therapy, AIDS (Disease), Pomalidomide, HIV, Drug approval, Antiretroviral agents, Sarcoma, Clinical trials, Diseases, Physicians, Respiratory system agents, Labels, Orphan drugs, Pharmaceuticals and cosmetics industries
Abstract

Bristol Myers Squibb announced that Pomalyst (pomalidomide) was approved by the US Food and Drug Administration (FDA) for patients with AIDS-related Kaposi sarcoma whose disease has become resistant to highly [...]

Published
2020

20. Sanofi,COs phase 3 IKEMA trial of Sarclisa in combo with carfilzomib & dexamethasone to treat relapsed MM meets primary endpoint

Subjects
Clinical trials, Carfilzomib, Pomalidomide, Multiple myeloma, Dexamethasone -- Product development, Glucocorticoids, Diseases, Industrial research, Pharmaceuticals and cosmetics industries
Abstract

Sanofi announced that phase 3 IKEMA clinical trial evaluating Sarclisa (isatuximab) added to carfilzomib and dexamethasone met the primary endpoint at its first planned interim analysis, demonstrating significantly prolonged progression-free [...]

Published
2020

21. CHMP recommends marketing approval for Sanofi's Sarclisa to treat relapsed and refractory MM

Subjects
Sanofi S.A., Pomalidomide, Marketing, Multiple myeloma, Pharmaceutical industry, Dexamethasone, Lenalidomide, Glucocorticoids, Diseases, Pharmaceuticals and cosmetics industries, European Union. European Commission
Abstract

The European Medicines AgencyÇÖs Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Sarclisa (isatuximab). The CHMP recommends Sarclisa in combination with pomalidomide and dexamethasone [...]

Published
2020

22. Sanofi says CHMP adopts positive opinion for Sarclisa

Subjects
Pomalidomide, Multiple myeloma, Recurrence (Disease), Dexamethasone, Lenalidomide, Glucocorticoids, Diseases, Business, News, opinion and commentary
Abstract

The European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, has adopted a positive opinion for Sarclisa. The CHMP recommends Sarclisa in combination with pomalidomide and dexamethasone [...]

Published
2020

23. New Small Lymphocytic Lymphoma Study Findings Have Been Reported from University of Tennessee (Medication Adherence, Health Care Utilization, and Costs Among Patients Initiating Oral Oncolytics for Multiple Myeloma or Chronic Lymphocytic ...)

Subjects
Ibrutinib, Health care costs, Physical fitness, Idelalisib, Pomalidomide, Patient compliance, Cancer patients, Lymphomas, Cancer research, Cancer, Tumors, Obesity, Editors, Health, The University of Tennessee
Abstract

2020 MAR 14 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Current study results on Oncology - Small Lymphocytic Lymphoma have been published. [...]

Published
2020

24. Bristol Myers Squibb phase 3 ELOQUENT-1 study evaluating Empliciti plus Revlimid & dexamethasone to treat MM fails to meet endpoint

Subjects
Bristol-Myers Squibb Co., Elotuzumab, Pomalidomide, Multiple myeloma -- Development and progression -- Care and treatment, Pharmaceutical industry, Dexamethasone, Labels, Lenalidomide, Glucocorticoids, Diseases, Pharmaceuticals and cosmetics industries, Revlimid (Medication)
Abstract

Bristol Myers Squibb Company announced topline results from ELOQUENT-1, a phase 3, randomized, open-label trial evaluating the combination of Empliciti (elotuzumab) plus Revlimid (lenalidomide) and dexamethasone (ERd), versus Revlimid and [...]

Published
2020

25. US FDA approves Sanofi's Sarclisa in combo with pomalidomide & dexamethasone to treat RRMM

Subjects
United States. Food and Drug Administration, Sanofi S.A., Monoclonal antibodies, Pomalidomide, Multiple myeloma -- Drug therapy, Pharmaceutical industry, Drug approval, Dexamethasone, Antibodies, Recurrence (Disease), Lenalidomide, Glucocorticoids, Diseases, Pharmaceuticals and cosmetics industries
Abstract

The US Food and Drug Administration (FDA) has approved Sarclisa (isatuximab-irfc) in combination with pomalidomide and dexamethasone (pom-dex) for the treatment of adults with relapsed refractory multiple myeloma (RRMM) who [...]

Published
2020

26. Researchers at Laboratory of Systems Pharmacology Detail Findings in Cancer (Development and Characterization of a Wee1 Kinase Degrader)

Subjects
Novartis Pharmaceuticals UK Ltd., Physical fitness, Cancer -- Drug therapy, Pomalidomide, Olaparib, Cancer research, Pharmaceutical industry, Finance, Cell cycle, Pharmacology, DNA, Cancer cells, Obesity, DNA damage, Characterization, Editors, Health
Abstract

2020 FEB 15 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators discuss new findings in Cancer. According to news originating from Boston, [...]

Published
2020

27. Janssen seeks US FDA approval for Darzalex in combo with Kyprolis & dexamethasone to treat relapsed/refractory MM

Subjects
United States. Food and Drug Administration, Johnson & Johnson, Carfilzomib, Pomalidomide, Multiple myeloma -- Drug therapy, Daratumumab, Pharmaceutical industry, Drug approval, Dexamethasone, Recurrence (Disease), Glucocorticoids, Pharmaceuticals and cosmetics industries, Darzalex (Medication)
Abstract

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a supplemental Biologics License Application (sBLA) to the US Food and Drug Administration (FDA) seeking approval of Darzalex [...]

Published
2020

28. New Findings from Rutgers Cancer Institute of New Jersey in Hypersensitivity Provides New Insights (Pomalidomide desensitization for hypersensitivity: A case report)

Subjects
Physical fitness, Cancer, Pomalidomide, Medical research, Multiple myeloma, Allergy, Obesity, Cancer research, Recurrence (Disease), Immune system, Editors, Health
Abstract

2020 JAN 4 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Current study results on Immune System Diseases and Conditions - Hypersensitivity have [...]

Published
2020

29. Patent Issued for Soluble C5aR Antagonists (USPTO 10,487,098)

Subjects
Ixazomib, Angiotensin II -- Intellectual property, Palifermin -- Intellectual property, Monoclonal antibodies, Tofacitinib, Immunosuppressive agents, Fluocinolone, Halcinonide -- Intellectual property, Ciclesonide, Tixocortol, Olmesartan medoxomil -- Intellectual property, Physical fitness, Tocilizumab, Clobetasone -- Intellectual property, Nilotinib, Obinutuzumab, Antineoplastic agents -- Intellectual property, Canakinumab, Anopheles, Fingolimod, Belimumab, Basiliximab, Obesity, Alefacept, Everolimus, Ibrutinib, Ocrelizumab, Editors, Cannabidiol, Brentuximab vedotin, Pomalidomide, Belatacept, Panobinostat, Health
Abstract

2019 DEC 14 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- A patent by the inventors Fan, Pingchen (Fremont, CA); Krasinski, Antoni (Sunnyvale, [...]

Published
2019

30. Patent Application Titled 'Amanitin Antibody Conjugates' Published Online (USPTO 20190328899)

Subjects
Carfilzomib, Elotuzumab -- Intellectual property, B cells, Pomalidomide, Amino acids -- Intellectual property, Stem cells, Daratumumab, Biological products -- Intellectual property, Antibodies, Editors, Health
Abstract

2019 NOV 18 (NewsRx) -- By a News Reporter-Staff News Editor at Stem Cell Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a patent application [...]

Published
2019

31. Recent Findings from University of Messina Has Provided New Data on Adverse Drug Reactions (Ototoxic Adverse Drug Reactions: A Disproportionality Analysis Using the Italian Spontaneous Reporting Database)

Subjects
Etoricoxib -- Analysis -- Reports, Efavirenz -- Analysis -- Reports, Physical fitness -- Analysis -- Reports, Tapentadol -- Analysis -- Reports, Databases -- Analysis -- Reports, Drugs -- Analysis -- Reports, Nebivolol -- Analysis -- Reports, Antineoplastic agents -- Analysis -- Reports, Deferasirox -- Analysis -- Reports, Pemetrexed, Pomalidomide, Obesity, Marketing, Vincristine, Editors, CD-ROM catalog, Database, CD-ROM database, Health
Abstract

2019 NOV 16 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Research findings on Drugs and Therapies - Adverse Drug Reactions are discussed [...]

Published
2019

32. Study Data from Celgene Corporation Provide New Insights into Pharmacy Practice (Rems Pharmacy Tasks: the Adoption of an Innovative Electronic Support System)

Subjects
Celgene Corp., Physical fitness, Electronic warfare, Pomalidomide, Pharmacy, Drugstores, Pharmaceutical industry, Risk assessment, Obesity, Lenalidomide, Editors, Health
Abstract

2019 OCT 19 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators discuss new findings in Drugs and Therapies - Pharmacy Practice. According [...]

Published
2019

33. Researchers Submit Patent Application, 'SOLUBLE C5aR ANTAGONISTS', for Approval (USPTO 20190270761)

Subjects
Ixazomib, Angiotensin II -- Intellectual property, Palifermin -- Intellectual property, Monoclonal antibodies, Tofacitinib, Immunosuppressive agents, Fluocinolone, Halcinonide -- Intellectual property, Ciclesonide, Tixocortol, Olmesartan medoxomil -- Intellectual property, Physical fitness, Tocilizumab, Clobetasone -- Intellectual property, Nilotinib, Obinutuzumab, Antineoplastic agents -- Intellectual property, Canakinumab, Anopheles, Fingolimod, Belimumab, Basiliximab, Obesity, Alefacept, Everolimus, Ibrutinib, Ocrelizumab, Editors, Cannabidiol, Brentuximab vedotin, Pomalidomide, Belatacept, Panobinostat, Health
Abstract

2019 SEP 28 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- From Washington, D.C., NewsRx journalists report that a patent application by the [...]

Published
2019

34. Patent Application Titled 'A Highly Stable, Protease-Resistant E. Coli Asparaginase' Published Online (USPTO 20190270978)

Subjects
Hydrolysis, Asparagine, Physical fitness, Pamidronate -- Intellectual property, Proteases -- Intellectual property, Aspartate -- Intellectual property, Carboplatin -- Intellectual property, Fludrocortisone, Fluoxymesterone -- Intellectual property, Antineoplastic agents -- Intellectual property, Suramin -- Intellectual property, Escherichia coli, Amino acids, Sorafenib, Pemetrexed, Temsirolimus, Pomalidomide, Carfilzomib, Obesity, Everolimus, Asparaginase, BCG, Vincristine, Editors, Sunitinib, Health
Abstract

2019 SEP 28 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a [...]

Published
2019

35. Bristol-Myers announces EC approval of EPd

Subjects
Bristol-Myers Squibb Co., Clinical trials, Pomalidomide, Multiple myeloma -- Development and progression, Pharmaceutical industry, Drug approval, Recurrence (Disease), Dexamethasone, Lenalidomide, Glucocorticoids, Business, News, opinion and commentary, European Union. European Commission
Abstract

Bristol-Myers Squibb Company announced that the European Commission, or EC, has approved Empliciti plus pomalidomide and low-dose dexamethasone, or EPd, for the treatment of adult patients with relapsed and refractory [...]

Published
2019

36. Findings from Taussig Cancer Center Update Understanding of Multiple Myeloma (Pomalidomide-Based Regimens for Treatment of Relapsed and Relapsed/Refractory Multiple Myeloma: Systematic Review and Meta-analysis of Phase 2 and 3 Clinical Trials)

Subjects
Physical fitness, Cancer, Recurrence (Disease), Daratumumab, Antineoplastic agents, Dexamethasone, Obesity, Bendamustine, Glucocorticoids, Pomalidomide, Editors, Carfilzomib, Bortezomib, Health
Abstract

2019 AUG 24 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators publish new report on Oncology - Multiple Myeloma. According to news [...]

Published
2019

37. Bristol-Myers announces positive CHMP opinion for Empliciti combination

Subjects
Bristol-Myers Squibb Co., Elotuzumab, Pomalidomide, Multiple myeloma -- Drug therapy, Pharmaceutical industry, Drug approval, Recurrence (Disease), Dexamethasone, Lenalidomide, Glucocorticoids, Business, News, opinion and commentary
Abstract

Earlier, Bristol-Myers (BMY) announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, has adopted a positive opinion on a Type-II variation application [...]

Published
2019

38. Bristol-Myers' Emplicit combination for myeloma granted positive CHMP opinion

Subjects
Bristol-Myers Squibb Co., Elotuzumab, Pomalidomide, Multiple myeloma, Pharmaceutical industry, Drug approval, Recurrence (Disease), Dexamethasone, Lenalidomide, Glucocorticoids, Business, News, opinion and commentary
Abstract

Bristol-Myers (BMY) announced that the Committee for Medicinal Products for Human Use, or (CHMP, of the European Medicines Agency, has adopted a positive opinion on a Type-II variation application for [...]

Published
2019

39. Patent Issued for Soluble C5aR Antagonists (USPTO 10,329,314)

Subjects
Tromethamine -- Intellectual property, Ixazomib, Angiotensin II -- Intellectual property, Palifermin -- Intellectual property, Monoclonal antibodies, Tofacitinib, Immunosuppressive agents, Fluocinolone, Halcinonide -- Intellectual property, Ciclesonide, Tixocortol, Olmesartan medoxomil -- Intellectual property, Physical fitness, Tocilizumab, Clobetasone -- Intellectual property, Nilotinib, Obinutuzumab, Antineoplastic agents -- Intellectual property, Canakinumab, Anopheles, Fingolimod, Belimumab, Basiliximab, Fashion designers, Obesity, Alefacept, Everolimus, Editors, Brentuximab vedotin, Pomalidomide, Belatacept, Health
Abstract

2019 JUL 13 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- ChemoCentryx Inc. (Mountain View, California, United States) has been issued patent number [...]

Published
2019

40. US FDA accepts for review Sanofi's BLA for isatuximab to treat relapsed/refractory multiple myeloma

Subjects
United States. Food and Drug Administration, Monoclonal antibodies, Pomalidomide, Antibodies, Dexamethasone, Clinical trials, Glucocorticoids, Antigenic determinants, Pharmaceuticals and cosmetics industries
Abstract

The US Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for isatuximab for the treatment of patients with relapsed/refractory multiple myeloma (RRMM). The target [...]

Published
2019

41. Researchers Submit Patent Application, 'Use Of Cannabinoids In The Treatment Of Multiple Myeloma', for Approval (USPTO 20190175547)

Subjects
Carfilzomib, Ixazomib, Physical fitness, B cells, Pomalidomide, Cannabinoids, Multiple myeloma, Phenols (Class of compounds) -- Intellectual property, Obesity, Cancer, Editors, Health
Abstract

2019 JUL 6 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- From Washington, D.C., NewsRx journalists report that a patent application by the [...]

Published
2019

42. US FDA approves Janssen's Darzalex in combo with lenalidomide and dexamethasone to treat patients MM who are transplant ineligible

Subjects
United States. Food and Drug Administration, Johnson & Johnson, Pomalidomide, Multiple myeloma -- Drug therapy, Stem cells, Daratumumab, Pharmaceutical industry, Drug approval, Lenalidomide, Dexamethasone, Stem cell transplantation, Death, Clinical trials, Glucocorticoids, Pharmaceuticals and cosmetics industries, Darzalex (Medication)
Abstract

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the US Food and Drug Administration (FDA) has approved Darzalex (daratumumab) in combination with lenalidomide and dexamethasone (Rd) for the treatment [...]

Published
2019

43. US FDA lifts partial clinical hold of AbbVie's phase 3 study of Venetoclax in patients with multiple myeloma

Subjects
United States. Food and Drug Administration, Roche Holding AG, Clinical trials, Venetoclax, Pomalidomide, Biotechnology industries, Medical research, Multiple myeloma -- Genetic aspects -- Care and treatment, Dexamethasone, Glucocorticoids, Pharmaceuticals and cosmetics industries
Abstract

AbbVie, announced that the US Food and Drug Administration (FDA) has lifted the partial clinical hold placed on CANOVA (M13-494), a phase 3 trial evaluating venetoclax (venclexta or venclyxto) for [...]

Published
2019

44. AbbVie: FDA lifts partial clinical hold on Phase 3 study of venetoclax

Subjects
United States. Food and Drug Administration, Venetoclax, Clinical trials, Pomalidomide, Dexamethasone, Glucocorticoids, Business, News, opinion and commentary
Abstract

AbbVie announced that the U.S. FDA has lifted the partial clinical hold placed on CANOVA (M13-494), a Phase 3 trial evaluating venetoclax for the investigational treatment of relapsed/refractory multiple myeloma. [...]

Published
2019

45. Researchers at Eisai Co. Ltd. Detail Findings in Toxicology and Pharmacology (Analysis of exposure margins in developmental toxicity studies for detection of human teratogens)

Subjects
Pharmacology, Physical fitness, Embryonic development, Pomalidomide, Toxicity, Obesity, Editors, Health
Abstract

2019 JUN 8 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators discuss new findings in Drugs and Therapies - Toxicology and Pharmacology. [...]

Published
2019

46. Celgene receives EC approvals for REVLIMID-, IMNOVID-based combination regimens

Subjects
Celgene Corp., Pharmaceutical industry, Multiple myeloma -- Drug therapy, Dexamethasone, Drug approval, Pomalidomide, Glucocorticoids, Lenalidomide, Bortezomib, Business, News, opinion and commentary, European Union. European Commission, Revlimid (Medication)
Abstract

Celgene Corporation announced that the European Commission has approved two new triplet regimens based on Celgene's proprietary IMiD treatments, REVLIMID and IMNOVID. REVLIMID in combination with bortezomib and dexamethasone, is [...]

Published
2019

47. Reports from Hospital Clinic Add New Data to Findings in Multiple Myeloma (Pomalidomide-dexamethasone for treatment of soft-tissue plasmacytomas in patients with relapsed / refractory multiple myeloma)

Subjects
Multiple myeloma -- Care and treatment, Dexamethasone, Physical fitness, Pomalidomide, Recurrence (Disease) -- Care and treatment, Steroids (Organic compounds), Obesity, Glucocorticoids, Novels, Editors, Health
Abstract

2019 MAR 16 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Data detailed on Oncology - Multiple Myeloma have been presented. According to [...]

Published
2019

48. Sanofi's phase 3 trial of isatuximab meets primary endpoint of prolonging progression free survival in patients with relapsed/refractory MM

Subjects
Sanofi S.A. -- Product development, Pharmaceutical industry -- Product development, Multiple myeloma -- Patient outcomes -- Care and treatment, Pomalidomide, Dexamethasone -- Product development, Steroids (Organic compounds), Glucocorticoids, Industrial research, Pharmaceuticals and cosmetics industries
Abstract

The pivotal phase 3 trial of Sanofi's isatuximab in patients with relapsed/refractory multiple myeloma met the primary endpoint of prolonging progression free survival in patients treated with isatuximab in combination [...]

Published
2019

49. Cancer drug shows benefits in treating anal lesions

Author

Otto, M. Alexander

Subjects
Celgene Corp., Papillomavirus infections -- Drug therapy, Pomalidomide, Pharmaceutical industry, Health, Health care industry
Abstract

AT THE END OF 6 MONTHS of low-dose pomalidomide (Pomalyst), more than half of men who have sex with men had partial or complete clearance of long-standing, grade 3 anal [...]

Published
2020

50. FDA approves pomalidomide for Kaposi sarcoma

Author

Mulcahy, Nick

Subjects
United States. Food and Drug Administration, Kaposi's sarcoma -- Drug therapy, Highly active antiretroviral therapy, Pomalidomide, Multiple myeloma -- Drug therapy, Drug approval, Health, Health care industry
Abstract

THE FOOD AND DRUG Administration has granted accelerated approval to pomalidomide for the treatment of AIDS-related Kaposi sarcoma that is resistant to highly active antiretroviral therapy (HAART) or that occurs [...]

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results